Ayuk, Francis and Wagner-Drouet, Eva-Maria and Wolff, Daniel and von Huenerbein, Natascha and von Pein, Ute-Marie and Klyuchnikov, Evgeny and von Harsdorf, Stephanie and Koenecke, Christian and Sayer, Herbert and Kroeger, Nicolaus (2024) Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study. BONE MARROW TRANSPLANTATION, 59 (8). pp. 1092-1096. ISSN 0268-3369, 1476-5365
Full text not available from this repository. (Request a copy)Abstract
Although most patients with chronic graft-versus-host disease (cGVHD) show initial response to first-line therapy, long-term clinically meaningful success of first-line treatment remains rare. In a prospective multicentre phase II trial in 6 German centers, patients with newly diagnosed moderate or severe cGVHD received prednisone and everolimus for 12 months followed by a 1-year follow-up period. Primary endpoint was treatment success (TS) at 6 months defined as patient being alive, achieving PR or CR of cGVHD, having no relapse of underlying disease and requiring no secondary treatment for cGVHD. Of the 34 patients evaluable for efficacy, 19 (56%) had TS at 6 months with 22 and 52% of the patients in a CR and PR respectively. Overall 30 patients (88%) had a CR or PR as best response, nearly all responses (29/30) occurring within the first 6 weeks of treatment. The cumulative incidence of treatment failure at 1 year was 63%, corresponding to 37% TS. Predefined safety endpoint (thrombotic microangiopathy, pneumonitis, and avascular necrosis) were not observed in any patient. Addition of everolimus to prednisolone is well tolerated and may improve long-term treatment success. Larger studies are necessary to ascertain the possible role of everolimus in first-line treatment of cGVHD.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | INITIAL TREATMENT; CHRONIC GVHD; SIROLIMUS; TRANSPLANTATION; CYCLOSPORINE; PNEUMONITIS; THERAPY; CORTICOSTEROIDS; RAPAMYCIN; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 16 Jan 2026 11:05 |
| Last Modified: | 16 Jan 2026 11:05 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65165 |
Actions (login required)
 |
View Item |
